On July 16, 2026 Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, reported Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix will present at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Drug Discovery and Development Conference taking place July 21-24, 2026 in Boston.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The AACR (Free AACR Whitepaper) Drug Discovery and Development Conference brings together leaders across oncology research and drug development, making it an ideal venue to provide a corporate update and showcase our progress with the ongoing Phase 1/2 ARIA study of REM-422," said Dr. Smith. "The clinical activity, durability of response and favorable safety results observed to date reinforce the potential of our RNA processing approach, and we look forward to discussing how this modality may offer a new therapeutic option for patients with MYB-driven cancers, including adenoid cystic carcinoma."
Presentation Details:
Session Title: Biotech Spotlight Session 1: Novel Therapeutics
Date and Time: July 24, 2026 at 2:50 PM ET
Location: Sheraton Boston Hotel
About REM-422
REM-422 is a potent, selective, and oral small molecule mRNA degrader that induces the reduction of MYB mRNA and subsequent protein expression. REM-422 functions by facilitating the incorporation of a poison exon in the MYB mRNA transcript, leading to nonsense-mediated decay of the transcript. REM-422 is currently in a Phase 1/2 clinical study in Adenoid Cystic Carcinoma (ACC) and a Phase 1 clinical study in Acute Myeloid Leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). The U.S. Food and Drug Administration granted REM-422 Orphan Drug Designation for ACC and AML and Fast Track designation for ACC.
About the ARIA (A study of REM-422 In Adenoid cystic carcinoma) Clinical Trial
This Phase 1/2, open-label, non-randomized, multicenter study (NCT06118086) is investigating REM-422 in patients with recurrent, metastatic or unresectable Adenoid Cystic Carcinoma (ACC). The study includes a Dose Escalation Phase and a Dose Expansion Phase. The purpose of the Dose Escalation Phase is to determine the maximum tolerated dose and/or recommended Phase 2 dose (RP2D) of REM-422 in patients with recurrent, metastatic, or unresectable ACC. The purpose of Dose Expansion is to further evaluate the safety and anti-tumor activity of the REM-422 RP2D in biomarker positive patients.
About Adenoid Cystic Carcinoma
Adenoid cystic carcinoma (ACC) is a solid tumor that most commonly arises in the salivary glands characterized by frequent recurrent, perineural invasion and dysregulation of the MYB oncogene. Depending on the location of the tumor, symptoms may include numbness of the face, difficulties swallowing, changes in vision, or difficulty breathing, among others. Many therapeutic approaches, such as chemotherapy, kinase inhibitors, and immunotherapy have been studied in ACC with modest or disappointing results, and there remain no approved treatment options.
(Press release, Remix Therapeutics, JUL 16, 2026, https://www.globenewswire.com/news-release/2026/07/16/3328319/0/en/remix-therapeutics-to-present-at-aacr-drug-discovery-and-development-conference.html [SID1234669278])